Clinical Trial Update: A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of SGN-B6A in Chinese participants with advanced solid tumors has completed, reporting safety and preliminary activity across multiple cancer in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• SGN-B6A

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: COMPLETED